The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
SKYTROFA Specialised Therapeutics Pharma Pty Ltd
Product name
SKYTROFA
Accepted date
May-2024
Active ingredients
lonapegsomatropin
Proposed indication
Growth failure in children and adolescents due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD]).
Application type
A (new medicine)
Publication date
May-2024